SBI Securities Co. Ltd. Invests $464,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SBI Securities Co. Ltd. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 651 shares of the biopharmaceutical company's stock, valued at approximately $464,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its stake in Regeneron Pharmaceuticals by 107.7% in the 4th quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company's stock worth $578,000 after acquiring an additional 421 shares during the last quarter. Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in the 4th quarter. Bailard Inc. now owns 13,422 shares of the biopharmaceutical company's stock worth $9,561,000 after acquiring an additional 1,236 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Regeneron Pharmaceuticals by 8.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 952 shares of the biopharmaceutical company's stock worth $669,000 after acquiring an additional 72 shares during the last quarter. Keynote Financial Services LLC increased its stake in Regeneron Pharmaceuticals by 8.2% in the 4th quarter. Keynote Financial Services LLC now owns 539 shares of the biopharmaceutical company's stock worth $384,000 after acquiring an additional 41 shares during the last quarter. Finally, John G Ullman & Associates Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $2,361,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on REGN. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price objective on the stock. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Finally, Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Up 1.7 %

NASDAQ REGN traded up $11.66 on Wednesday, reaching $687.15. 828,674 shares of the stock traded hands, compared to its average volume of 608,258. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a fifty day moving average price of $696.58 and a 200-day moving average price of $857.92. The company has a market cap of $75.12 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $11.86 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.